

ERRATUM

## Erratum to: Adding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study

Yujing Jin · Xiaowei Sun · Xichen Zhao · Tiehong Zhu

Published online: April 11, 2017

© The Author(s) 2017. This article is an open access publication

Erratum to: Diabetes Ther  
DOI 10.1007/s13300-017-0247-6

In the original publication, the data have been incorrectly updated within the results, discussion and Table 2. The correct data are given here.

The result in Table 2, presenting Hypoglycemic events at Week 12 currently reads: 2 (1.7).

This result should read: 2 (3.2).

The result in Table 2 presenting Hypoglycemic events at Week 36 reads: 3 (2.5).

This result should read: 3 (4.8).

The result in Table 2 presenting the Hypoglycemic events *p* value currently reads: 1.000.

This *p* value should read: 0.500.

The statement within the results section reads:

‘There was no significant difference in the incidence of hypoglycemia before and after treatment (1.7% vs. 2.5%  $\chi^2 = 0.21$ ;  $p = 1.000$ ) (Table 2).’

This statement should read:

‘There was no significant difference in the incidence of hypoglycemia before and after treatment (3.2% vs. 4.8%  $\chi^2 = 0.50$ ;  $p = 0.500$ ) (Table 2).’

The statement the discussion section reads: ‘In particular, the 40% of subjects in the present study who.’

This statement should read: ‘In particular, the 36.7% of subjects in the present study who.’

---

The online version of the original article can be found under doi:[10.1007/s13300-017-0247-6](https://doi.org/10.1007/s13300-017-0247-6).

---

Y. Jin · X. Sun · X. Zhao · T. Zhu (✉)  
Tianjin Medical University General Hospital,  
Tianjin 300052, China  
e-mail: zhutiehong@tmu.edu.cn

**Table 2** Changes in clinical parameters after 24 weeks' basal-plus treatment

Parameters <sup>a</sup>	Week 12 ( <i>n</i> = 63)	Week 36 ( <i>n</i> = 63)	Mean difference (SD)	<i>p</i> value
HbA1c (%)	8.06 (0.71)	7.17 (0.54)	0.89 (0.56)*	<0.001
FBG (mmol/L)	6.23 (0.15)	6.20 (0.16)	0.03 (0.14)	0.118
PBG (mmol/L)	13.17 (1.72)	10.14 (2.20)	3.03 (1.53)*	<0.001
Basal insulin dosage (IU/kg/day)	0.36 (0.06)	0.35 (0.05)	0.01 (0.02)	0.073
Prandial insulin dosage (IU/kg/day)	0 (0)	0.14 (0.04)	0.14 (0.04)*	<0.001
Total insulin dosage (IU/kg/day)	0.36 (0.06)	0.50 (0.08)	0.14 (0.03)*	<0.001
Weight (kg)	73.19 (6.82)	73.28 (6.90)	0.08 (0.76)	0.379
Number of OADs used	2.71 (0.46)	2.12 (0.42)	0.60 (0.61)*	<0.001
OADs, <i>n</i> (%)				
α-glycosidase inhibitor	63 (100)	22 (34.9)		
Metformin	18 (28.6)	63 (100)		
Insulin secretagogue	59 (93.7)	10 (15.9)		
Hypoglycemic events, <i>n</i> (%)	2 (3.2)	3 (4.8)		0.500
Other adverse events, <i>n</i> (%)	0 (0)	0 (0)		

*HbA1c* glycated hemoglobin A1c, *FBG* fasting blood glucose, *PBG* postprandial blood glucose, *OADs* oral antidiabetic drugs

\* *p* < 0.01

<sup>a</sup> Parameters are summarized as mean (SD) unless specified

**Open Access.** This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any non-

commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.